P082 Circulating Mir-145 as a Marker of Therapeutic Response in Patients With Ankylosing Spondylitis Receiving Anti-TNF Therapy

doi 10.1136/annrheumdis-2018-ewrr2018.99

Full Text

Abstract

Available in

Date

February 21, 2018

Authors

Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Anti-TNF Therapy in Ankylosing Spondylitis: Insights for the Clinician

Therapeutic Advances in Musculoskeletal Disease

Sports Medicine

English

Recommendations for Starting Anti TNF-α in Patients With Ankylosing Spondylitis

English

Anti TNF-α Therapy Might Be Responsible for an Increased Incidence of Varicocele in Patients With Ankylosing Spondylitis

Turkish Journal of Medical Sciences

English

Changes in MiRNA-5196 Expression as a Potential Biomarker of Anti-TNF-Α Therapy in Rheumatoid Arthritis and Ankylosing Spondylitis Patients

Archivum Immunologiae et Therapiae Experimentalis

English

A Prospective Clinical Investigation of the Effects of Anti-TNF Alpha Therapy on Exercise Capacity in Patients With Ankylosing Spondylitis

Turkish Journal of Medical Sciences

English

Response to Anti-TNF-Α Treatment for Secondary Renal Amyloidosis in a Patient With Ankylosing Spondylitis

English

Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study

Clinical Genitourinary Cancer

English

First Update of the International ASAS Consensus Statement for the Use of Anti-TNF Agents in Patients With Ankylosing Spondylitis

Annals of the Rheumatic Diseases

Molecular Biology

English

Anti-Tumour Necrosis Factor Therapy for Ankylosing Spondylitis: International Experience

Annals of the Rheumatic Diseases

Molecular Biology

English